Last reviewed · How we verify
SB213503 lot 3
SB213503 is a selective antagonist of the chemokine receptor CCR3, which blocks eosinophil recruitment and activation in inflammatory airway diseases.
SB213503 is a selective antagonist of the chemokine receptor CCR3, which blocks eosinophil recruitment and activation in inflammatory airway diseases. Used for Asthma (eosinophilic phenotype), Allergic airway inflammation.
At a glance
| Generic name | SB213503 lot 3 |
|---|---|
| Also known as | GSK Biologicals combined diphteria, tetanus, acellular pertussis and inactivated poliovirus lot 3 vaccine |
| Sponsor | GlaxoSmithKline |
| Drug class | CCR3 antagonist |
| Target | CCR3 |
| Modality | Biologic |
| Therapeutic area | Respiratory/Immunology |
| Phase | Phase 3 |
Mechanism of action
CCR3 is highly expressed on eosinophils and plays a central role in their migration to sites of inflammation. By antagonizing CCR3, SB213503 reduces eosinophil infiltration into airways and tissues, thereby decreasing inflammatory responses. This mechanism is particularly relevant in eosinophilic airway diseases where eosinophil accumulation drives pathology.
Approved indications
- Asthma (eosinophilic phenotype)
- Allergic airway inflammation
Common side effects
- Headache
- Upper respiratory tract infection
- Nasopharyngitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB213503 lot 3 CI brief — competitive landscape report
- SB213503 lot 3 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI